416PDFinal results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer
Nordquist, L T, Ghanbari, H, Elist, J J, Oliver, J C, Gannon, W, Shahlaee, A, Fuller, S, Shore, NVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy279.404
Date:
October, 2018
File:
PDF, 77 KB
2018